ArticleJournal of neuro-oncology2026
Radiosensitivity index stability across glioma progression: a longitudinal bulk and single-cell analysis.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeThe radiosensitivity index (RSI) is a transcriptomic predictor of intrinsic radiosensitivity. The longitudinal behavior of the RSI in glioma and its variation across intratumoral cellular states have been unknown. We investigated RSI dynamics between matched primary and recurrent gliomas and examined RSI heterogeneity at single-cell resolution.
methodsThe RSI was calculated using the Eschrich 10-gene model in 214 matched primary–recurrent glioma pairs from the GLASS Consortium (bulk RNA-seq) and in 6,863 malignant cells from 28 IDH-wildtype glioblastomas profiled by Smart-seq2. Longitudinal changes were assessed by Wilcoxon’s signed-rank test. A survival analysis used Kaplan–Meier and Cox regression. Cell state-specific RSI differences were evaluated by the Kruskal–Wallis test with Bonferroni-corrected pairwise comparisons.
resultsThe bulk RSI showed no significant change between primary and recurrent tumors (ΔRSI = + 0.009 ± 0.096, p = 0.17), with a strong primary–recurrent correlation (r = 0.65, p < 0.001). We observed a marginal RSI increase in the IDH-wildtype tumors (ΔRSI = + 0.019, p = 0.042). The Kaplan–Meier analysis suggested shorter survival in RSI-increasing tumors (median 31 vs. 47 months, log-rank p = 0.040), but the RSI change was not independent in multivariable Cox regression (HR = 0.83, p = 0.82). At single-cell resolution, neural progenitor cell (NPC)-like cells exhibited the lowest RSI (Kruskal–Wallis p = 3.0 × 10⁻⁵), though effect sizes were small (rank-biserial r = 0.06–0.09).
conclusionThe bulk RSI remains stable across glioma progression, and the RSI change does not independently predict survival. The single-cell analysis revealed significant but biologically modest RSI variation across cellular states, suggesting limited resolution of the RSI signature at the single-cell level.
Indexed as
Identifiers
41984136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.